| Literature DB >> 26801469 |
Dirk Bassler1, Katharina F Mueller2, Matthias Briel3, Jos Kleijnen4, Ana Marusic5, Elizabeth Wager6, Gerd Antes7, Erik von Elm8, Douglas G Altman9, Joerg J Meerpohl7.
Abstract
OBJECTIVE: The aim of this study is to review highly cited articles that focus on non-publication of studies, and to develop a consistent and comprehensive approach to defining (non-) dissemination of research findings.Entities:
Keywords: Dissemination bias; MEDICAL ETHICS; OPEN Project; Publication Bias; QUALITATIVE RESEARCH
Mesh:
Year: 2016 PMID: 26801469 PMCID: PMC4735132 DOI: 10.1136/bmjopen-2015-010024
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Various reasons for selective publication.
Characteristics that need to be considered when disseminating research findings (What?)
| Type of data | Format/product | Accessibility |
|---|---|---|
|
Individual data complete* incomplete† Summary (analysed) data complete* incomplete† |
Grey literature (press, newspaper, any kind of report, patent, technical report from government agencies or scientific research groups, working paper from research groups or committees, executive summary, book chapter, presentation at scientific conferences (abstracts, slides, posters), dissertation/ thesis, trial register entry, submission to regulatory authorities, database/statistical file*‡, regulatory drug trial reports) Full article published in a journal Regulatory documents (CSR (clinical study report), ISS (integrated summary of effectiveness or safety), PSURS (periodic safety updates), DAP (drug approval packages), EPAR (European public assessment report), CTD (common technical documents)) Study protocol, statistical analysis plan Case report forms Internal communication |
Open to all Available on request Restricted§ Not available outside primary research group |
*All raw data.
†Selection of outcome data.
‡Analysed outcome data.
§Including paywall restrictions.
Responsibility/influence that different players could assume in the various steps of conducting a clinical trial and in the dissemination of clinical trial documents (Who?)
| Players in the dissemination process | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Steps in trial conduct and dissemination | Researchers authors | Journal editors | Peer reviewers of journal articles | Funding agencies | Pharmaceutical and medical device manufacturers | Research ethics committees | Research institutions | Regulatory agencies | Trial register | Decision making bodies* | Readers/patients/patient organisations/benefit assessment agencies/HTA bodies |
| Research idea/research question | x | x | x | x | x | ||||||
| Writing the study protocol | x | x | x | x | x | ||||||
| Registering the study in a trial register | x | x | x | x | x | x | x | x | x | ||
| Submitting the study protocol for a journal publication | x | x | x | x | x | x | x | x | |||
| Publishing the study protocol | x | x | x | x | x | ||||||
| Conducting the study/assessing outcome measures | x | x | |||||||||
| Analysing data | x | x | x | ||||||||
| Writing and submitting a journal article | x | x | |||||||||
| Peer review | x | x | |||||||||
| Publishing journal research | x | x | x | x | x | x | |||||
*Decision-making authorities in healthcare systems (eg, legal entities, such as the Federal Joint Committee in Germany).
Motivations of players that might lead to biased dissemination of research result (Why?)
| Players | Motivations |
|---|---|
| Researchers/authors | Publish or perish
The importance of scientists’ work is often judged by the amount of papers they publish. Journal publications not only improve the visibility and reputation of investigators, but also represent an increasingly important prerequisite for faculty positions and research funding. Junior and especially mid-career researchers are in need of frequent publications to progress their academic careers, as survival in the system of science depends on reaching a critical amount of publications within a certain time Novel research findings are especially rewarded. Confirmations of one's own expectations with significant results might be used as proof by researchers that the procedure and findings are sound. Furthermore, a non-significant finding may be interpreted as failure and therefore less ‘valuable’ or less ‘publishable’, as various surveys and experiments have described Apart from the tendency to confirm their own expectations and hypotheses, researchers wish to demonstrate the truth of their own hypothesis to keep this research area open and not limit the chance for further findings Researchers/authors might be pushed by funders/industry/lobby to report/submit research findings in favour of the product and not submit unfavourable data. Researchers might be pushed to preferably publish results that support the current practice in their respective medical specialty as conflicting results might be damaging to the reputation and financial interest of their profession |
| Journal editors | Frequent citations
Editors are interested in publishing articles that accrue many citations, since frequent citations increase the journal's prestige and attract more readers, authors and subscribers. Editors will try to anticipate the interest of readers (who will probably be more interested in new and impressive results). Confirmations of editor's expectations and significant results might be used as proof by editors that the procedure and findings are sound Journals receive financial rewards for publishing (eg, reprint sales or advertising revenue) Personal conflicts of interest might influence editors’ decision about manuscripts |
| Peer reviewers | Tendency to confirm own expectations and hypotheses Confirmations of peer reviewer's expectations and significant results might be used as proof by peer reviewers that the procedure and findings are sound Peer reviewers have a very labour-intensive task Consequently, at times, well-designed and conducted studies may not be published if they report null or negative results Personal conflicts of interest might influence peer reviewers’ decision about manuscripts |
| (pharmaceutical and device) manufacturers | Marketing of their product
Commercial sponsors are interested in results supporting their product, and try to use such results in the most favourable way for the marketing of their product. Likewise, they may wish to suppress studies when the results do not favour their product |
| Funding agencies | Increase in visibility
Funding agencies want to be visible and associated with promising research Funding agencies, in particular public funders such as hospitals, might be influenced by economic considerations, and therefore favour less expensive treatment options over new and more costly alternatives |
| Research ethics committees | Lack of financial and personal resources
While many research ethics committees sporadically check publications of approved studies, they lack the financial and personal resources to do so in a systematic manner While many research ethics committees would prefer to require trial registration and unbiased dissemination of trial findings, most countries currently lack the legal basis for them to do so |
| Research institutions | Increase in visibility
Research institutions want to be visible and associated with promising research Conflicts of interest related to the performance of their own institution |
| Regulatory agencies | Lack of realising the public interest in unbiased research
While regulatory agencies need to protect commercial interests, their transparency policies explicitly state that the public interest in unbiased clinical data can overrule the commercial interests (especially after marketing approval has been granted). Nevertheless, recent decision making of the European Medicines Agency on more or less restricted access to trial data did not consider ‘public interest’ arguments |
| Decision making bodies* | Have an interest in transparency and try to add to the dissemination process through their submission and publishing procedures |
| Readers/patients/patient organisations | Readers and patients might be more interested in ‘positive’ or new research findings |
*Decision-making authorities in European healthcare systems, such as the Federal Joint Committee in Germany.